We would like to eludicate the role of dopamine on glucose metabolism.
ID
Source
Brief title
Condition
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Glucose productions (suppression)
Secondary outcome
n.a.
Background summary
(page 2-4 vof the protocol)
It has been hypothesized that dopamine (DA) may be involved in the modulation
of glucose metabolism. This hypothesis is partly based on the observation of
the relationship between schizophrenia and diabetes and the finding that lean
drug-naive schizophrenic patients display hepatic insulin resistance.
Intriguingly, animal studies suggest a key role for pre-autonomic neurons in
the hypothalamus in the regulation of hepatic glucose production and hepatic
insulin sensitivity through sympathetic as well as parasympathetic outflow via
the brain stem nuclei to the liver. This suggests an association between
dopamine and insulin sensitivity. We want to elucidate the role of dopamine in
the regulation of insulin sensitivity through a dopamine depletion challenge.
This role may be important since dopamine modulating medication is widely
prescribed for disorders as for instance ADHD, Parkinson and schizophrenia.
Study objective
We would like to eludicate the role of dopamine on glucose metabolism.
Study design
The insuline sensitivity will be analyised in a group of 10 healthy subjects,
by means of two hyperinsulinemic euglycemic clamps. One of these clamps will be
performed after dopamine depletion with AMPT.
Intervention
One of the clamps will be performed after dopamine depletion with AMPT.
Study burden and risks
Stabile isotopes are not radioactiev and are therefor harmless. AMPT can cause
sleepiness, and rigidity of muscles. Patients will be in hospital for about 7
hours.
Meibergdreef 9
1105 AZ Amsterdam
Nederland
Meibergdreef 9
1105 AZ Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
Male
Aged between 18 and 35
Exclusion criteria
1. Type I and II diabetes mellitus or any other chronic disease
2. Renal insufficiency or elevated liver enzymes
3. Family history of type II diabetes mellitus.
4. Primary dyslipidemia
5. Use of any drugs
6. Alcohol consumption in excess of 3 units per day or in the last 3 days before the clamp
7. History of drug abuse
8. Performance of vigorous exercise
9. History of psychiatric disorders
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| EudraCT | EUCTR2008-006142-25-NL |
| CCMO | NL19322.018.08 |